Diabetes · 2006 · 95 citations · 24 references
MedicineEndocrinologyInternal MedicineBone MetabolismCardiovascular PharmacotherapyDiabetologyDiabetes MellitusEndothelial DysfunctionDiabetes-associated Vascular ChangesOsteoprotegerin RegulationSandwich Enzyme-linked Immunosorbent Assay
Osteoprotegerin is a recently identified inhibitor of bone resorption. Recent studies indicate that osteoprotegerin also acts as an important regulatory molecule in the vasculature. The purpose of this study was to investigate the relationship between plasma osteoprotegerin levels and endothelium-dependent arterial dilation in type 2 diabetic patients. The study subjects included 40 newly diagnosed type 2 diabetic patients and 46 healthy subjects. All patients were given insulin therapy for 6 months. Plasma osteoprotegerin concentration was measured in duplicate by a sandwich enzyme-linked immunosorbent assay method, and high-resolution ultrasound was used to measure brachial artery diameter at rest, after reactive hyperemia, and after sublingual glyceryltrinitrate. The plasma osteoprotegerin level in patients before treatment was 3.36 +/- 0.32 ng/l, which was significantly higher than that in control subjects (2.38 +/- 0.25 ng/l, P < 0.001). After 6 months of treatment, osteoprotegerin levels decreased markedly (2.83 +/- 0.34 ng/l, P < 0.001). Flow-mediated endothelium-dependent arterial dilation in patients before treatment was 3.21 +/- 0.52%, which was significantly lower than that in control subjects (4.46 +/- 0.56%, P < 0.01), and it improved markedly after 6 months of treatment (4.03 +/- 0.49%, P < 0.01). In multivariate analysis, osteoprotegerin was significantly associated with endothelium-dependent arterial dilation, fasting blood glucose (FBG), HbA(1c) (A1C), and ultrasensitive C-reactive protein (CRP) at baseline (P < 0.01). The absolute changes in osteoprotegerin showed significant correlation with changes in endothelium-dependent arterial dilation, FBG, A1C, and CRP in diabetic patients during the course of treatment (P < 0.01). This study shows that plasma osteoprotegerin levels are elevated in newly diagnosed diabetic patients and are significantly associated with endothelial function.
24
Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density
W. Scott Simonet, Dave Lacey, Colin R. Dunstan et al. · Cell · 1997 · 5.1K citations · Full text
Osteoprotegerin Is a Receptor for the Cytotoxic Ligand TRAIL
John G. Emery, Peter McDonnell, Michael Brigham Burke et al. · Journal of Biological Chemistry · 1998 · 1.2K citations · Full text
Hosung Min, Sean Morony, Ildiko Sarosi et al. · The Journal of Experimental Medicine · 2000 · 559 citations · Full text